GCLabs

Search for Test Items

Chromogranin A

GC Labs code	N132	Test Field	Tumor marker
Compulsory forms

GC Labs code

N132

Test Field

Tumor marker

Compulsory forms

Information

Test method	ELISA (Enzyme linked immunosorbent assay)
Specimen (mL)	S 1.0 Heparin P 1.0
Specimen storage	Frozen
Specimen stability	Refrigerated (7 days)
Test schedule	Wed
Analytical time (day)	1

Test method

ELISA (Enzyme linked immunosorbent assay)

Specimen (mL)

S 1.0
Heparin P 1.0

Specimen storage

Frozen

Specimen stability

Refrigerated (7 days)

Test schedule

Wed

Analytical time (day)

Reference range/Unit	[Plasma] ≤ 108.00 (ng/mL) [Serum] ≤ 108.00 (ng/mL)
Clinical Significance	Chromogranin-A (CgA) is an acidic glycoprotein expressed in the secretory granules of most normal and neoplastic neuroendocrine (NE) cell types, where it is released together with peptide hormones and biogenic amines. Neuroendocrine tumors (NETs) are a form of cancer that differ from other neoplasia in that they synthesize, store, and secrete peptides, e.g., CgA and amines. CgA is secreted from neuroendocrine-derived tumors including foregut, midgut and hindgut gastrointestinal NETs, pheochromocytomas, neuroblastomas, medullary thyroid carcinomas, some pituitary tumors, functioning and non-functioning pancreatic NETs. Significantly elevated CgA levels have been found in patients with other diseases, such as impaired renal function, untreated benign essential hypertension, gastritis, prostatic carcinoma, and hyperparathyroidism. The best-characterized circulating biomarker that identifies NETs in general is CgA. Monitoring blood CgA levels may effectively provide information that is helpful in delineating tumor burden and rate of tumor growth, predicting tumor response to therapy and providing some indication as to prognosis.
Remark	Gastric acid inhibitors can stimulate CgA secretion in neuroendocrine tissues, causing significant increase in CgA levels. Medication should be stopped two weeks before the test.

Reference range/Unit

 [Plasma]
≤ 108.00 (ng/mL)

 [Serum]
≤ 108.00 (ng/mL)

Clinical Significance

Chromogranin-A (CgA) is an acidic glycoprotein expressed in the secretory granules of most normal and neoplastic neuroendocrine (NE) cell types, where it is released together with peptide hormones and biogenic amines. Neuroendocrine tumors (NETs) are a form of cancer that differ from other neoplasia in that they synthesize, store, and secrete peptides, e.g., CgA and amines. CgA is secreted from neuroendocrine-derived tumors including foregut, midgut and hindgut gastrointestinal NETs, pheochromocytomas, neuroblastomas, medullary thyroid carcinomas, some pituitary tumors, functioning and non-functioning pancreatic NETs.
Significantly elevated CgA levels have been found in patients with other diseases, such as impaired renal function, untreated benign essential hypertension, gastritis, prostatic carcinoma, and hyperparathyroidism. The best-characterized circulating biomarker that identifies NETs in general is CgA. Monitoring blood CgA levels may effectively provide information that is helpful in delineating tumor burden and rate of tumor growth, predicting tumor response to therapy and providing some indication as to prognosis.

Remark

Gastric acid inhibitors can stimulate CgA secretion in neuroendocrine tissues, causing significant increase in CgA levels. Medication should be stopped two weeks before the test.